Cited by 2,340Hemoglobinopathies and Related DisordersBlood groups and transfusionHemophilia Treatment and Research

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

Open access

Charache, Samuel, Terrin, Michael L., Moore, Richard D., Dover, George J., Barton, Franca B., Eckert, Susan V., McMahon, Robert P., Bonds, Duane R.·1995·New England Journal of Medicine

DOI 10.1056/nejm199505183322001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises. METHODS: In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months. RESULTS: Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P < 0.001). The median times to the first crisis (3.0 vs. 1.5 months, P = 0.01) and the second crisis (8.8 vs. 4.6 months, P < 0.001) were longer with hydroxyurea treatment. Fewer patients assigned to hydroxyurea had chest syndrome (25 vs. 51, P < 0.001), and fewer underwent transfusions (48 vs. 73, P = 0.001). At the end of the study, the doses of hydroxyurea ranged from 0 to 35 mg per kilogram of body weight per day. Treatment with hydroxyurea did not cause any important adverse effects. CONCLUSIONS: Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year. Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect. The beneficial effects of hydroxyurea do not become manifest for several months, and its use must be carefully monitored. The long-term safety of hydroxyurea in patients with sickle cell anemia is uncertain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199505183322001

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An introduction to probability theory and its applications
(1958) · Journal of the Franklin Institute · doi:10.1016/0016-0032(58)90688-4 · Cited by 29,621
Applied Regression Analysis
Draper, N. R., & Smith, H. (2005) · Technometrics · doi:10.1198/tech.2005.s303 · Cited by 17,993
Practical Nonparametric Statistics (2nd ed).
Groeneveld, R. A., & Conover, W. J. (1981) · Journal of the American Statistical Association · doi:10.2307/2287607 · Cited by 1,869
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B. A., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 532
Self-citation
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., Eckert, S. V., Ballas, S., Koshy, M., Milner, P., Orringer, E., Phillips, G., & Platt, O. (1992) · Blood · doi:10.1182/blood.v79.10.2555.2555 · Cited by 438
Self-citation
5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.
DeSimone, J., Heller, P., Hall, L., & Zwiers, D. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.14.4428 · Cited by 384
Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication
Lori, F., Malykh, A., Cara, A., Sun, D. K., Weinstein, J. N., Lisziewicz, J., & Gallo, R. C. (1994) · Science · doi:10.1126/science.7973634 · Cited by 317
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G. J., Moore, R. D., et al. (1992) · Blood · doi:10.1182/blood.v79.10.2555.bloodjournal79102555 · Cited by 301
Self-citation
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
Dover, G. J., Brusilow, S. W., & Charache, S. (1994) · Blood · doi:10.1182/blood.v84.1.339.bloodjournal841339 · Cited by 229
Self-citation

Show all 26 references

Research works printed but not linked: 10

Dover GJ, 1994, Blood, 84, 339, 10.1182/blood.V84.1.339.339 · DOI
1994, Blood, 84, 404a
Kalbfleisch JD, Prentice RL. The stastistical analysis of failure time data. New York: John Wiley, 1980:1-20, 70-142.
Ferm VH, 1966, Arch Pathol, 81, 174
Weichselbaum RR, Hallahan DE, Chen GTY. Biological and physical basis to radiation oncology. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:539-66.
Chemotherapeutic agents. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer medicine. 3rd ed. Vol. 1. Philadelphia: Lea & Febiger, 1993:698-814.
Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia: W.B. Saunders, 1995:166-94.
Fruchtman SM, 1994, Blood, 84, 518a
Boivin P, 1993, Nouv Rev Fr Hematol, 35, 491
Triadou P, 1994, Nouv Rev Fr Hematol, 36, 367

Sorted by citations

Items 301–400 of 1,004

Reproductive issues in sickle cell disease
Smith‐Whitley, K. (2014) · Blood · doi:10.1182/blood-2014-07-577619 · Cited by 90
Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia
Wang, W. C., Oyeku, S. O., Luo, Z., Boulet, S. L., Miller, S. T., Casella, J. F., Fish, B., Thompson, B. W., & Grosse, S. D. (2013) · PEDIATRICS · doi:10.1542/peds.2013-0333 · Cited by 89
GENITOURINARY COMPLICATIONS OF SICKLE CELL DISEASE
BRUNO, D., Wigfall, D. R., Zimmerman, S. A., Rosoff, P. M., & Wiener, J. S. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65841-7 · Cited by 89
MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice
Belcher, J. D., Young, M. A., Chen, C., Nguyen, J., Burhop, K. E., Tran, P. D., & Vercellotti, G. M. (2013) · Blood · doi:10.1182/blood-2013-02-486282 · Cited by 88
Barriers to hydroxyurea adherence and health‐related quality of life in adolescents and young adults with sickle cell disease
Badawy, S. M., Thompson, A. A., Penedo, F. J., Lai, J., Rychlik, K. L., & Liem, R. I. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12878 · Cited by 90
“Using ©MMAS8, adherence level was defined as: low (0 to <6), medium (6 to <8) or high (8).”
Background
Update in Hematology
Catlett, J., & Alving, B. M. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-2-200201150-00011 · Cited by 89
Molecular therapies in β‐thalassaemia
Quek, L., & Thein, S. L. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06408.x · Cited by 88
A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy
Estepp, J. H., Smeltzer, M. P., Kang, G., Li, C., Wang, W. C., Abrams, C., Aygun, B., Ware, R. E., Nottage, K., & Hankins, J. S. (2017) · American Journal of Hematology · doi:10.1002/ajh.24906 · Cited by 88
“days, with a median (IQR, range) duration of 30 (28-30, 1-60) days.”
Background
Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Chaine, B., Neonato, M. G., Girot, R., & Aractingi, S. (2001) · PubMed · Cited by 88
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice
Meiler, S. E. L., Wade, M. F., Kutlar, F., Yerigenahally, S. D., Xue, Y., Parseval, L. M., Corral, L. G., Swerdlow, P. S., & Kutlar, A. (2011) · Blood · doi:10.1182/blood-2010-11-319137 · Cited by 88
Photoregulation of RNA Digestion by RNase H with Azobenzene-Tethered DNA
Matsunaga, D., Asanuma, H., & Komiyama, M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0471976 · Cited by 88
A psychometric evaluation of the PedsQL™ Family Impact Module in parents of children with sickle cell disease
Panepinto, J. A., Hoffmann, R. G., & Pajewski, N. M. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-32 · Cited by 88
Butyrate increases the efficiency of translation of γ-globin mRNA
Weinberg, R. S., Ji, X., Sutton, M., Perrine, S. P., Galperin, Y., Li, Q., Liebhaber, S. A., Stamatoyannopoulos, G., & Atweh, G. F. (2004) · Blood · doi:10.1182/blood-2004-02-0454 · Cited by 88
How I treat acute chest syndrome in children with sickle cell disease
Miller, S. T. (2011) · Blood · doi:10.1182/blood-2010-11-261834 · Cited by 87
Sickle Cell Disease
Azar, S., & Wong, T. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.09.009 · Cited by 86
“thrombosis risk through reductions in neutrophil and platelet counts and decreased RBC adhesion molecule expression.(74,85) Hydroxyurea is indicated for adult patients with SCD who have 3 or more pain ep-”
Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation
Bartolucci, P., Chaar, V., Picot, J., Bachir, D., Habibi, A., Fauroux, C., Galactéros, F., Colin, Y., Kim, C. L. V., & Nemer, W. E. (2010) · Blood · doi:10.1182/blood-2009-12-257444 · Cited by 87
Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells
Brun, M., Bourdoulous, S., Couraud, P., Élion, J., Krishnamoorthy, R., & Lapouméroulie, C. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500176 · Cited by 87
The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease
Wun, T. (2000) · Hematology · doi:10.1080/10245332.2000.11746536 · Cited by 87
Cost of hospitalizations associated with sickle cell disease in the United States.
Davis, H., Moore, R. M., & Gergen, P. J. (1997) · Europe PMC (PubMed Central) · Cited by 87
Self-citation
Sickle Cell and the Brain
Adams, R. J., Ohene‐Frempong, K., & Wang, W. C. (2001) · Hematology · doi:10.1182/asheducation-2001.1.31 · Cited by 87
Effects of hydroxyurea treatment for patients with hemoglobin SC disease
Luchtman‐Jones, L., Pressel, S., Hilliard, L., Brown, R. C., Smith, M. G., Thompson, A. A., Lee, M. T., Rothman, J., Rogers, Z. R., Owen, W., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24255 · Cited by 86
“However, clinical trials have demonstrated that hydroxyurea is safe, beneficial, and cost-effective in reducing the frequency and intensity of painful events in adults, children, and infants as young as 9 months of age with homozygous sickle cell disease (HbSS) and HbS/b-thalassemia (HbSb) [1–4] Acute chest syndrome e…”
Background
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial
Helton, K. J., Adams, R. J., Kesler, K. L., Lockhart, A., Aygün, B., Driscoll, C. E., Heeney, M. M., Jackson, S. M., Krishnamurti, L., Miller, S. T., et al. (2014) · Blood · doi:10.1182/blood-2013-12-545186 · Cited by 86
Hematopoietic stem cell transplantation for sickle cell disease
Kassim, A. A., & Sharma, D. (2017) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2017.05.008 · Cited by 86
Exposure to hydroxyurea during pregnancy: a case series
Thauvin‐Robinet, C., Maingueneau, C., Robert, E. H., Éléfant, É., Guy, H., Caillot, D., Casasnovas, O., Douvier, S., & Nivelon‐Chevallier, A. (2001) · Leukemia · doi:10.1038/sj.leu.2402168 · Cited by 86
Induction of human γ globin gene expression by histone deacetylase inhibitors
Cao, H., Stamatoyannopoulos, G., & Jung, M. (2003) · Blood · doi:10.1182/blood-2003-02-0478 · Cited by 86
New therapies in sickle cell disease
Vichinsky, E. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09776-3 · Cited by 86
Gene therapy of hemoglobinopathies: progress and future challenges
Ikawa, Y., Miccio, A., Magrin, E., Kwiatkowski, J. L., Rivella, S., & Cavazzana, M. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz172 · Cited by 86
Inflammatory potential of neutrophils detected in sickle cell disease
Lum, A. F. H., Wun, T., Staunton, D. E., & Simon, S. I. (2004) · American Journal of Hematology · doi:10.1002/ajh.20059 · Cited by 85
Total THA in Adult Osteonecrosis Related to Sickle Cell Disease
Hernigou, P., Zilber, S., Filippini, P., Mathieu, G., Poignard, A., & Galactéros, F. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-007-0069-3 · Cited by 85
7 Sickle cell disease: clinical management
Ballas, S. K. (1998) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(98)80075-9 · Cited by 85
Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation
Canalli, A. A., Franco‐Penteado, C. F., Saad, S. T. O., Conran, N., & Costa, F. F. (2008) · Haematologica · doi:10.3324/haematol.12119 · Cited by 85
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease
Qureshi, A., Kaya, B., Pancham, S., Keenan, R., Anderson, J., Akanni, M., Howard, J., & the British Society for Haematology (2018) · British Journal of Haematology · doi:10.1111/bjh.15235 · Cited by 90
“Skin ulcers have been reported but do not seem to be any more frequent than in those not on hydroxycarbamide (Charache et al, 1995).”
BackgroundInfluential
Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype
Bonds, D. R. (2004) · Blood Reviews · doi:10.1016/j.blre.2004.04.002 · Cited by 84
Self-citation
Epidemiologia de internações por doença falciforme no Brasil
Loureiro, M. M., & Rozenfeld, S. (2005) · Revista de Saúde Pública · doi:10.1590/s0034-89102005000600012 · Cited by 84
Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review
DeBaun, M. R. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.959922 · Cited by 84
A zinc-finger transcriptional activator designed to interact with the γ-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts
Wilber, A. C., Tschulena, U., Hargrove, P. W., Kim, Y., Persons, D. A., Barbas, C. F., & Nienhuis, A. W. (2010) · Blood · doi:10.1182/blood-2009-08-240556 · Cited by 83
In vitro effects of NIPRISAN (Nix‐0699): a naturally occurring, potent antisickling agent
Iyamu, E. W., Turner, E., & Asakura, T. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03593.x · Cited by 82
Pain in Children and Adolescents With Sickle Cell Disease: An Analysis of Daily Pain Diaries
Gil, K. M., Porter, L. S., Ready, J., Workman, E., Sedway, J. A., & Anthony, K. K. (2000) · Children s Health Care · doi:10.1207/s15326888chc2904_1 · Cited by 83
Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients
Maïer-Redelsperger, M., de Montalembert, M., Flahault, A., Neonato, M. G., Ducrocq, R., Masson, M.-P., Girot, R., Élion, J., & the French Study Group on Sickle Cell Disease (1998) · Blood · doi:10.1182/blood.v91.12.4472 · Cited by 83
Nitric oxide therapy in sickle cell disease
Gladwin, M. T., & Schechter, A. N. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90027-7 · Cited by 82
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea
Almeida, C. B., de Souza, L. E. B., Leonardo, F. C., Costa, F. T. M., WERNECK, C. C., Covas, D. T., Costa, F. F., & Conran, N. (2015) · Blood · doi:10.1182/blood-2014-12-616250 · Cited by 81
“3 of action of HU in SCD is believed to be its ability to induce the production of fetal Hb (HbF) in erythrocytes, reducing HbS polymerization and red cell sickling.(18,19) However,”
Background
The Performance of the PedsQL Generic Core Scales in Children With Sickle Cell Disease
Panepinto, J. A., Pajewski, N. M., Foerster, L. M., & Hoffmann, R. G. (2008) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e31817e4a44 · Cited by 82
Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon‐α in 1sttrimester: Report of 3 cases and review of the literature
Mubarak, A. A., Kakil, I. R., Awidi, A., Homsi, U. A., Fawzi, Z. O., Kelta, M., & Al‐Hassan, A. (2002) · American Journal of Hematology · doi:10.1002/ajh.9876 · Cited by 82
Hydroxyurea reacts with heme proteins to generate nitric oxide
Pacelli, R., Taira, J., Cook, J. A., Wink, D. A., & Krishna, M. C. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91378-1 · Cited by 82
Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study
Lebensburger, J. D., Miller, S. T., Howard, T. H., Casella, J. F., Brown, C., Lü, M., Iyer, R. V., Sarnaik, S. A., Rogers, Z. R., Wang, W. C., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24037 · Cited by 80
Psychological interventions in childhood chronic illness.
Drotar, D. (2006) · American Psychological Association eBooks · doi:10.1037/11412-000 · Cited by 80
Long-term follow-up of pediatric sickle cell disease patients with abnormal high velocities on transcranial Doppler
Bernaudin, F., Verlhac, S., Co�c, L., Lesprit, E., Brugi�res, P., & Reinert, P. (2005) · Pediatric Radiology · doi:10.1007/s00247-005-1419-5 · Cited by 80
Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium
Zennadi, R., Chien, A. C., Xu, K., Batchvarova, M., & Telen, M. J. (2008) · Blood · doi:10.1182/blood-2008-01-134346 · Cited by 80
Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment
Fertrin, K. Y., & Costa, F. F. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.44 · Cited by 81
MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease.
Manfrè, L., Giarratano, E., Maggio, A., Banco, A., Vaccaro, G., & Lagalla, R. (1999) · American Journal of Roentgenology · doi:10.2214/ajr.173.6.10584785 · Cited by 80
Hydroxyurea for Children with Sickle Cell Disease
Heeney, M. M., & Ware, R. E. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.002 · Cited by 80
Sickle cell disease and pregnancy
Koshy, M. (1995) · Blood Reviews · doi:10.1016/0268-960x(95)90021-7 · Cited by 80
Sickle cell disease: a review
Roseff, S. D. (2009) · Immunohematology · doi:10.21307/immunohematology-2019-234 · Cited by 79
Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease
Faës, C., Ilich, A., Sotiaux, A., Sparkenbaugh, E., Henderson, M. W., Buczek, L., Beckman, J. D., Ellsworth, P., Noubouossie, D. F., Bhoopat, L., et al. (2019) · Blood · doi:10.1182/blood.2019000424 · Cited by 79
Follow‐up of sickle cell disease patients with priapism treated by hydroxyurea
Saad, S. T. O., Lajolo, C. P., Gilli, S. C. O., Marques, J. F. C., Lima, C. S. P., Costa, F. F., & Arruda, V. R. (2004) · American Journal of Hematology · doi:10.1002/ajh.20142 · Cited by 79
Hydroxyurea therapy for sickle cell disease in community‐based practices: A survey of Florida and North Carolina hematologists/oncologists
Zumberg, M. S., Reddy, S., Boyette, R. L., Schwartz, R. J., Konrad, T. R., & Lottenberg, R. (2005) · American Journal of Hematology · doi:10.1002/ajh.20353 · Cited by 79
Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease
Laurin, L., Nachman, P. H., Desai, P. C., Ataga, K. I., & Derebail, V. K. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft295 · Cited by 79
Prevention of conversion to abnormal transcranial D oppler with hydroxyurea in sickle cell anemia: A P hase III international randomized clinical trial
Hankins, J. S., McCarville, M. B., Rankine‐Mullings, A., Reid, M. E., Lobo, C. L. C., de Moura, P. G., Ali, S. B., Soares, D., Aldred, K., Jay, D. W., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24198 · Cited by 79
“Clinical benefits of hydroxyurea have been shown in both children and adults through reduction of frequency of pain and acute chest syndrome episodes [12,22,23].”
Background
Bone Marrow Transplantation for Sickle Cell Disease
Walters, M. C. (1999) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199911000-00005 · Cited by 78
Hydroxyurea: new insights on an old drug
Navarra, P. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00032-8 · Cited by 78
Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea
Nahavandi, M., Tavakkoli, F., Wyche, M. Q., Perlin, E., Winter, W. P., & Castro, O. L. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03919.x · Cited by 78
From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
Hankins, J. S., Aygun, B., Nottage, K., Thornburg, C., Smeltzer, M. P., Ware, R. E., & Wang, W. C. (2014) · Medicine · doi:10.1097/md.0000000000000215 · Cited by 77
The Role of Red Blood Cell Exchange Transfusion in the Treatment and Prevention of Complications of Sickle Cell Disease
Danielson, C. (2002) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2002.00396.x · Cited by 75
Peptidyl epoxides as selective protease inactivators
Albeck, A. (2000) · Drug Development Research · doi:10.1002/1098-2299(200007/08)50:3/4 · Cited by 12
Catalase-Mediated Nitric Oxide Formation from Hydroxyurea
Huang, J., Kim‐Shapiro, D. B., & King, S. B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030547z · Cited by 77
New Views of Sickle Cell Disease Pathophysiology and Treatment
Rosse, W. F., Narla, M., Petz, L. D., & Steinberg, M. H. (2000) · Hematology · doi:10.1182/asheducation-2000.1.2 · Cited by 77
Safety and efficacy of blood exchange transfusion for priapism complicating sickle cell disease
Ballas, S. K., & Lyon, D. (2015) · Journal of Clinical Apheresis · doi:10.1002/jca.21394 · Cited by 76
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease
Xu, J. Z., Conrey, A. K., Frey, I., Gwaabe, E., Menapace, L. A., Tumburu, L., Lundt, M., Lequang, T., Li, Q., Glass, K. E., et al. (2022) · Blood · doi:10.1182/blood.2022015403 · Cited by 76
PATHOPHYSIOLOGY OF VASO-OCCLUSION
Ballas, S. K., & Mohandas, N. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70396-8 · Cited by 76
Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload
Ware, R. E., Schultz, W. H., Yovetich, N. A., Mortier, N. A., Alvarez, O. A., Hilliard, L., Iyer, R. V., Miller, S. T., Rogers, Z. R., Scott, J. P., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23145 · Cited by 76
Cognitive deficits are associated with unemployment in adults with sickle cell anemia
Sanger, M., Jordan, L. C., Pruthi, S., Day, M. A., Covert, B. V., Merriweather, B., Rodeghier, M., DeBaun, M. R., & Kassim, A. A. (2016) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2016.1149153 · Cited by 76
“Moreover, we found no significant difference in hydroxyurea use between the employed and unemployed groups, even though hydroxyurea, the only disease-modifying therapy approved for SCD, has been shown to significantly reduce the frequency of pain episodes and ACS, and to decrease morbidity and mortality (Charache et a…”
Background
Hydroxyurea Treatment for Sickle Cell Disease
Steinberg, M. H. (2002) · The Scientific World JOURNAL · doi:10.1100/tsw.2002.295 · Cited by 74
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population‐based cohort
Quarmyne, M., Wei, D., Theodore, R. S., Anand, S. S., Barry, V., Adisa, O. A., Buchanan, I. D., Bost, J. E., Brown, R. C., Joiner, C. H., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24587 · Cited by 75
Response to hydroxyurea in β thalassemia major and intermedia: Experience in western India
Italia, K. Y., Jijina, F. F., Merchant, R. H., Panjwani, S., Nadkarni, A. H., Sawant, P. M., Nair, S. B., Ghosh, K., & Colah, R. B. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.06.019 · Cited by 75
Development of the PedsQL™ sickle cell disease module items: qualitative methods
Panepinto, J. A., Torres, S., & Varni, J. W. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9941-4 · Cited by 81
Pulmonary Hypertension in Hemolytic Disorders
Machado, R. F., & Gladwin, M. T. (2010) · CHEST Journal · doi:10.1378/chest.09-3057 · Cited by 75
Sickle Cell Disease: From Membrane Pathophysiology to Novel Therapies for Prevention of Erythrocyte Dehydration
Brugnara, C. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200312000-00004 · Cited by 75
Ischemia-Reperfusion Injury in Sickle Cell Disease
Ansari, J., & Gavins, F. N. E. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.12.012 · Cited by 81
Neuropsychological Functioning in Preschool-age Children with Sickle Cell Disease: The Role of Illness-related and Psychosocial Factors
Tarazi, R. A., Grant, M., Ely, E. A., & Barakat, L. P. (2006) · Child Neuropsychology · doi:10.1080/09297040600611312 · Cited by 75
Hydroxyurea and Acute Painful Crises in Sickle Cell Anemia: Effects on Hospital Length of Stay and Opioid Utilization During Hospitalization, Outpatient Acute Care Contacts, and at Home
Ballas, S. K., Bauserman, R. L., McCarthy, W. F., Castro, O. L., Smith, W. R., & Waclawiw, M. A. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2010.03.020 · Cited by 74
The role of hydroxyurea in the management of sickle cell disease
Davies, S. C., & Gilmore, A. (2003) · Blood Reviews · doi:10.1016/s0268-960x(02)00074-7 · Cited by 74
Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA)
Sumoza, A., Bisotti, R., Sumoza, D., & Fairbanks, V. F. (2002) · American Journal of Hematology · doi:10.1002/ajh.10205 · Cited by 74
Phase I and pharmacokinetic study of Triapine®, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies
Gojo, I., Tidwell, M. L., Greer, J. M., Takebe, N., Seiter, K. P., Pochron, M. F., Johnson, B. L., Sznol, M., & Karp, J. E. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.01.004 · Cited by 74
A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease
Creary, S. E., Gladwin, M. T., Byrne, M., Hildesheim, M. E., & Krishnamurti, L. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.24931 · Cited by 73
“The short study duration may explain why we did not detect significant changes in participants’ effectiveness or global satisfaction TSQM-9 scores, since the clinical benefits of HU therapy can take 4 months to manifest [14].”
Background
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease
Kroner, B. L., Hankins, J. S., Pugh, N. L., Kutlar, A., King, A. A., Shah, N., Kanter, J., Glassberg, J., Treadwell, M. J., & Gordeuk, V. R. (2022) · American Journal of Hematology · doi:10.1002/ajh.26495 · Cited by 73
“Hydroxyurea therapy for sickle cell disease increases hemoglobin F, reduces pain crises, acute chest syndrome, and blood transfusions, and possibly increases survival.(5) Hydroxyurea is an Received: 21 December 2021 Revised: 3 February 2022 Accepted: 7 February 2022”
Background
Leg Ulcers in Sickle Cell Disease: Current Patterns and Practices
Delaney, K., Axelrod, K. C., Buscetta, A. J., Hassell, K. L., Adams-Graves, P. E., Seamon, C. A., Kato, G. J., & Minniti, C. P. (2013) · Hemoglobin · doi:10.3109/03630269.2013.789968 · Cited by 73
A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex–mismatched bone marrow transplantation
Kean, L. S., Durham, M. M., Adams, A. B., Hsu, L. L.-Y., Perry, J. R., Dillehay, D. L., Pearson, T. C., Waller, E. K., Larsen, C. P., & Archer, D. R. (2002) · Blood · doi:10.1182/blood.v99.5.1840 · Cited by 73
LEG ULCERS IN SICKLE CELL DISEASE
Eckman, J. R. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70404-4 · Cited by 73
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.
Little, J. A., McGowan, V., Kato, G. J., Partovi, K. S., Feld, J. J., Marić, I., Martyr, S. E., Taylor, J. G., Machado, R. F., Heller, T., et al. (2006) · PubMed · Cited by 73
Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond
Egesa, W. I., Nakalema, G., Waibi, W. M., Turyasiima, M., Amuje, E., Kiconco, G., Odoch, S., Kumbakulu, P. K., Abdirashid, S., & Asiimwe, D. (2022) · International Journal of Pediatrics · doi:10.1155/2022/3885979 · Cited by 89
“The earliest clinical trials on the effects of HU on children and adults with SCD were conducted in the early 90s [147, 148].”
Background
Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease
Grigg, A. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01290.x · Cited by 72
Hydroxyurea in Children with Sickle Cell Disease
Olivieri, N. F., & Vichinsky, E. P. (1998) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199801000-00004 · Cited by 70
AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain
Field, J. J., Ballas, S. K., Campbell, C. M., Crosby, L. E., Dampier, C., Darbari, D. S., McClish, D. K., Smith, W. R., & Zempsky, W. T. (2018) · Journal of Pain · doi:10.1016/j.jpain.2018.12.003 · Cited by 73
Microfluidic assessment of red blood cell mediated microvascular occlusion
Man, Y., Kucukal, E., An, R., Watson, Q. D., Bosch, J., Zimmerman, P. A., Little, J. A., & Gurkan, U. A. (2020) · Lab on a Chip · doi:10.1039/d0lc00112k · Cited by 73
Hydroxyurea in sickle cell disease—A study of clinico-pharmacological efficacy in the Indian haplotype
Italia, K. Y., Jain, D., Gattani, S., Jijina, F. F., Nadkarni, A. H., Sawant, P. M., Nair, S., Mohanty, D., Ghosh, K., & Colah, R. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2008.08.003 · Cited by 71
Pharmacologic Modulation of Fetal Hemoglobin
Steinberg, M. H., & Rodgers, G. P. (2001) · Medicine · doi:10.1097/00005792-200109000-00007 · Cited by 71
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles
Gerotziafas, G., Dreden, P. V., Chaari, M., Galea, V., Khaterchi, A., Lionnet, F., Stankovic-Stojanovic, K., Blanc‐Brude, O., Woodhams, B. J., Maïer-Redelsperger, M., et al. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0689 · Cited by 71
Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases
Nudelman, A. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(00)01199-5 · Cited by 71
Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea
Ballas, S. K., Marcolina, M. J., Dover, G. J., & Barton, F. B. (1999) · British Journal of Haematology · doi:10.1111/j.1365-2141.1999.01339.x · Cited by 71
Self-citation
Financial analysis of chronic transfusion for stroke prevention in sickle cell disease
Wayne, A. S., Schoenike, S., & Pegelow, C. H. (2000) · Blood · doi:10.1182/blood.v96.7.2369 · Cited by 71

Authors: Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R.
Affiliations: Johns Hopkins University (US)
Maryland Medical Research Institute (US)
National Heart, Lung, and Blood Institute (US)
ORCID: Terrin, Michael L.
Moore, Richard D.
Barton, Franca B.
McMahon, Robert P.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-05-18
Volume: 332
Issue: 20
Pages: 1317-1322
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199505183322001
OpenAlex: W2313541759
Semantic Scholar: 2c0939e2f6480b519903bb15870e5b894887e70d
Cited by: 2,340
References: 26
Citations by year: 2026: 67 · 2025: 97 · 2024: 77 · 2023: 88 · 2022: 95 · 2021: 92 · 2020: 80 · 2019: 78 · 2018: 85 · 2017: 104 · 2016: 114 · 2015: 101 · 2014: 82 · 2013: 79 · 2012: 73
FWCI: 34.43
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
National Institutes of Health (5u01hl045696-05)
National Heart, Lung, and Blood Institute (UO1-HL 45696, UO1 HL 45692, U01HL045692)
National Center for Research Resources (RR00046, M01RR000046)
Topics: Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Health Sciences › Medicine › Hematology › Blood groups and transfusion
Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
Keywords: hydroxyurea, sickle cell disease, vaso-occlusive crisis, fetal hemoglobin, blood transfusion, myelosuppression, treatment efficacy, adverse effects
MeSH terms: Adult, Anemia, Sickle Cell, Double-Blind Method, Female, Follow-Up Studies, Humans, Hydroxyurea, Male, Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks